{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T13:58:27Z","timestamp":1789912707012,"version":"4.0.1"},"reference-count":26,"publisher":"Walter de Gruyter GmbH","issue":"0","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,1,17]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We compared the Elia CTD Screen (ECS), a fluoroenzymeimmunoassay incorporating 17 human antinuclear antigens (ANA), with indirect immunofluorescence (IIF) on Hep-2 cells in order to determine the clinical utility of the ECS in additon to or without IIF.<\/jats:p><jats:p>We examined 1708 consecutive serum samples submitted for ANA testing using the ECS and IIF in parallel. Positive screen results were further examined by quantitative fluoroenzymeimmunoassays and\/or immunoblots for antibody identification. The medical records were evaluated for systemic rheumatic disorders.<\/jats:p><jats:p>Concordance between ECS and IIF was observed in 1344 (78.8%) samples. ECS had a better detection rate for anti-dsDNA, -SSA\/Ro, -SSB\/La, -U1RNP and -Jo-1 antibodies, whereas IIF was superior in the detection of anti-CENP-B antibodies as well as anti-histone, -nucleosome and -Pl-12 antibodies, which are not included in the ECS antigen panel. ECS had a 100% sensitivity for Sj\u00f6gren\u2019s syndrome, systemic sclerosis and Sharp syndrome. The sensitivity for Sj\u00f6gren\u2019s syndrome was slightly higher for ESC than for IIF (94%). IIF had a higher diagnostic sensitivity for systemic lupus erythematosus, indeterminated connective tissue disease, Raynaud\u2019s syndrome and limited scleroderma, compared to ESC (100% vs. 80%, 100 vs. 75%, 89 vs. 57%, 100 vs. 88.9%).<\/jats:p><jats:p>Our results suggest that the ECS represents an appropriate diagnostic tool for ANA screening. However, since some antigens are not incorporated in the ECS panel, and some ANA can also be missed by IIF, sequential or parallel screening with ECS and IIF may be reasonable when the clinical suspicion for connective tissue disease is high.<\/jats:p>","DOI":"10.1515\/cclm-2015-1051","type":"journal-article","created":{"date-parts":[[2015,12,17]],"date-time":"2015-12-17T17:18:27Z","timestamp":1450372707000},"source":"Crossref","is-referenced-by-count":9,"title":["Comparison of the clinical utility of the Elia CTD Screen to indirect immunofluorescence on Hep-2 cells"],"prefix":"10.1515","volume":"0","author":[{"given":"Christoph","family":"Robier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Amouzadeh-Ghadikolai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Stettin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Reicht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","reference":[{"key":"ref191","first-page":"183","article-title":"Can an ELISA replace immunofluorescence fort he detection of anti-nuclear antibodies? The routine use of anti-nuclear antibody screening ELISAs","volume":"53","year":"2007","journal-title":"Clin Lab"},{"key":"ref211","first-page":"52","article-title":"How should a distict general hospital immunology service screen for anti-nuclear antibodies? An \u201cin-the-field\u201d audit","volume":"180","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1373\/clinchem.2005.058552","article-title":"Antibodies to extractable nuclear antigens in antinuclear antibody-negative samples","volume":"51","year":"2005","journal-title":"Clin Chem"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0009-9120(02)00342-9","article-title":"Antinuclear antibodies (ANA) screening by enzyme immunoassay with nuclear Hep-2 cell extract and recombinant antigens: analytical and clinical evaluation","volume":"35","year":"2002","journal-title":"Clin Biochem"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1093\/clinchem\/48.12.2171","article-title":"Detection of specific antinuclear reactivities in patients with negative anti-nuclear antibody immunofluorescence screening tests","volume":"48","year":"2002","journal-title":"Clin chem"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"e0134218","DOI":"10.1371\/journal.pone.0134218","article-title":"Antinuclear antibodies in patients with psoriatic arthritis treated or not with biologics","volume":"10","year":"2015","journal-title":"PLoSOne"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2013-203863","article-title":"International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies","volume":"73","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1373\/clinchem.2005.058552","article-title":"Antibodies to extractable nuclear antigens in antinuclear antibody-negative samples","volume":"51","year":"2005","journal-title":"Clin Chem"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1196\/annals.1398.038","article-title":"Performance of antinuclear antibody connective tissue disease screen","volume":"1109","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/jcp.2010.084756","article-title":"Sensitivity of the Phadia Elia connective tissue disease screen for less common disease-specific autoantibodies","volume":"64","year":"2011","journal-title":"J Clin Pathol"},{"key":"ref11","first-page":"1155","article-title":"Screening of antinuclear antibodies: comparison between enzyme immunoassay based on nuclear homogenates, purified or recombinant antigens and immunofluorescence assay","volume":"42","year":"2004","journal-title":"Clin Chem Lab Med"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1196\/annals.1398.038","article-title":"Performance of antinuclear antibody connective tissue disease screen","volume":"1109","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1136\/annrheumdis-2013-204793","article-title":"Detection of antinuclear antibodies: added value of solid phase assay?","volume":"73","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2013-203863","article-title":"International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies","volume":"73","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"ref141","first-page":"1155","article-title":"Screening of antinuclear antibodies: comparison between enzyme immunoassay based on nuclear homogenates, purified or recombinant antigens and immunofluorescence assay","volume":"42","year":"2004","journal-title":"Clin Chem Lab Med"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1093\/clinchem\/48.12.2171","article-title":"Detection of specific antinuclear reactivities in patients with negative anti-nuclear antibody immunofluorescence screening tests","volume":"48","year":"2002","journal-title":"Clin chem"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1136\/annrheumdis-2013-204793","article-title":"Detection of antinuclear antibodies: added value of solid phase assay?","volume":"73","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.autrev.2011.06.005","article-title":"Detection of antinuclear antibodies by indirect immunofluorescence and by solid phase assay","volume":"10","year":"2011","journal-title":"Autoimmune Rev"},{"key":"ref111","first-page":"167","volume-title":"CURRENT Rheumatology diagnosis and treatment","year":"2007"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0009-9120(02)00342-9","article-title":"Antinuclear antibodies (ANA) screening by enzyme immunoassay with nuclear Hep-2 cell extract and recombinant antigens: analytical and clinical evaluation","volume":"35","year":"2002","journal-title":"Clin Biochem"},{"key":"ref81","first-page":"52","article-title":"How should a distict general hospital immunology service screen for anti-nuclear antibodies? An \u201cin-the-field\u201d audit","volume":"180","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"ref61","first-page":"183","article-title":"Can an ELISA replace immunofluorescence fort he detection of anti-nuclear antibodies? The routine use of anti-nuclear antibody screening ELISAs","volume":"53","year":"2007","journal-title":"Clin Lab"},{"key":"ref241","first-page":"167","volume-title":"CURRENT Rheumatology diagnosis and treatment","year":"2007"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"e0134218","DOI":"10.1371\/journal.pone.0134218","article-title":"Antinuclear antibodies in patients with psoriatic arthritis treated or not with biologics","volume":"10","year":"2015","journal-title":"PLoSOne"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.autrev.2011.06.005","article-title":"Detection of antinuclear antibodies by indirect immunofluorescence and by solid phase assay","volume":"10","year":"2011","journal-title":"Autoimmune Rev"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/jcp.2010.084756","article-title":"Sensitivity of the Phadia Elia connective tissue disease screen for less common disease-specific autoantibodies","volume":"64","year":"2011","journal-title":"J Clin Pathol"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2015-1051\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T23:51:44Z","timestamp":1619049104000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2015-1051\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,17]]},"references-count":26,"journal-issue":{"issue":"0"},"URL":"https:\/\/doi.org\/10.1515\/cclm-2015-1051","relation":{},"ISSN":["1437-4331","1434-6621"],"issn-type":[{"value":"1437-4331","type":"electronic"},{"value":"1434-6621","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1,17]]}}}